Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented in a poster session as part of the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place June 4-8, 2021.
These are the first-in-human data of CDX-527, the first candidate developed from Celldex’s bispecific platform which utilizes the Company’s proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway.
“We are encouraged by this emerging initial data where we have observed a good safety profile along with promising pharmacodynamic and pharmacokinetic activity, which are important key hurdles for the development of bispecific antibodies,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “While we are still early in the dose escalation phase, we are excited to advance into higher dose cohorts and evaluate the data further as the study progresses. We believe this preliminary data provides further validation of our preclinical studies and demonstrates the potential of our bispecific platform to produce next generation candidates.”